Glycoprotein N subtypes of human cytomegalovirus induce a strain-specific antibody response during natural infection

Journal of General Virology

Volumn 90, Issue 8, 2009, Pages 1951-1961

  Burkhardt, Christiane ^a   Himmelein, Susanne ^a,d   Britt, William ^b   Winkler, Thomas ^c   Mach, Michael ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN N; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; GLYCOPROTEIN N, HUMAN CYTOMEGALOVIRUS; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS STRAIN; AMINO ACID SEQUENCE; BLOOD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; IMMUNOLOGY; MOLECULAR GENETICS; SERODIAGNOSIS;

HUMAN HERPESVIRUS 5;

AMINO ACID SEQUENCE; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GENOTYPE; HUMANS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; POLYMORPHISM, GENETIC; VIRAL ENVELOPE PROTEINS;

EID: 69449088474     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.010967-0     Document Type: Article

References (56)

1. Abe, Y., Takashita, E., Sugawara, K., Matsuzaki, Y., Muraki, Y. & Hongo, S. (2004). Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A/H3N2 virus hemagglutinin. J Virol 78, 9605-9611.
2. Adler, S. P., Starr, S. E., Plotkin, S. A., Hempfling, S. H., Buis, J., Manning, M. L. & Best, A. M. (1995). Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 171, 26-32.
3. Adler, B., Scrivano, L., Ruzcics, Z., Rupp, B., Sinzger, C. & Koszinowski, U. (2006). Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J Gen Virol 87, 2451-2460.
4. Andreoni, M., Faircloth, M., Vugler, L. & Britt, W. J. (1989). A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J Virol Methods 23, 157-167.
5. Baboonian, C., Blake, K., Booth, J. C. & Wiblin, C. N. (1989). Complement-independent neutralising monoclonal antibody with differential reactivity for strains of human cytomegalovirus. J Med Virol 29, 139-145.
6. Bale, J. F., Jr, Petheram, S. J., Souza, I. E. & Murph, J. R. (1996). Cytomegalovirus reinfection in young children. J Pediatr 128, 347-352.
7. Boppana, S. B., Rivera, L. B., Fowler, K. B., Mach, M. & Britt, W. J. (2001). Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 344, 1366-1371.
8. Borst, E. M., Hahn, G., Koszinowski, U. H. & Messerle, M. (1999). Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol 73, 8320-8329.
9. Britt, W. (2006). Human cytomegalovirus infections and mechanisms of disease. In Cytomegaloviruses: Molecular Biology and Immunology, pp. 1-28. Edited by M. J. Reddehase. Wymondham, UK: Caister Academic Press.
10. Britt, W. J. & Auger, D. (1985). Identification of a 65 000 dalton virion envelope protein of human cytomegalovirus. Virus Res 4, 31-36.
11. Britt, W. J., Vugler, L., Butfiloski, E. J. & Stephens, E. B. (1990). Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 64, 1079-1085.
12. Chandler, S. H. & McDougall, J. K. (1986). Comparison of restriction site polymorphisms among clinical isolates and laboratory strains of human cytomegalovirus. J Gen Virol 67, 2179-2192.
13. Chandler, S. H., Handsfield, H. H. & McDougall, J. K. (1987). Isolation of multiple strains of cytomegalovirus from women attending a clinic for sexually transmitted disease. J Infect Dis 155, 655-660.
14. Chou, S. W. (1989). Reactivation and recombination of multiple cytomegalovirus strains from individual organ donors. J Infect Dis 160, 11-15.
15. Chou, S. W. (1990). Differentiation of cytomegalovirus strains by restriction analysis of DNA sequences amplified from clinical specimens. J Infect Dis 162, 738-742.
16. Coaquette, A., Bourgeois, A., Dirand, C., Varin, A., Chen, W. & Herbein, G. (2004). Mixed cytomegalovirus glycoprotein B genotypes in immunocompromised patients. Clin Infect Dis 39, 155-161.
17. Datsenko, K. A. & Wanner, B. L. (2000). One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 97, 6640-6645.
18. Farroway, L. N., Gorman, S., Lawson, M. A., Harvey, N. L., Jones, D. A., Shellam, G. R. & Singleton, G. R. (2005). Transmission of two Australian strains of murine cytomegalovirus (MCMV) in enclosure populations of house mice (Mus domesticus). Epidemiol Infect 133, 701-710.
19. Ghiasi, H., Perng, G.-C., Nesburn, A. B. & Wechsler, S. L. (2000). Antibody-dependent enhancement of HSV-1 infection by anti-gK sera. Virus Res 68, 137-144.
20. Gillet, L. & Stevenson, P. G. (2007). Antibody evasion by the N terminus of murid herpesvirus-4 glycoprotein B. EMBO J 26, 5131-5142.
21. Gorman, S., Harvey, N. L., Moro, D., Lloyd, M. L., Voigt, V., Smith, L. M., Lawson, M. A. & Shellam, G. R. (2006). Mixed infection with multiple strains of murine cytomegalovirus occurs following simultaneous or sequential infection of immunocompetent mice. J Gen Virol 87, 1123-1132.
22. Grundy, J. E., Lui, S. F., Super, M., Berry, N. J., Sweny, P., Fernando, O. N., Moorhead, J. & Griffiths, P. D. (1988). Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet 2, 132-135.
23. Inada, T., Chong, K. T. & Mims, C. A. (1985). Enhancing antibodies, macrophages and virulence in mouse cytomegalovirus infection. J Gen Virol 66, 871-878.
24. Ishibashi, K., Tokumoto, T., Tanabe, K., Shirakawa, H., Hashimoto, K., Kushida, N., Yanagida, T., Inoue, N., Yamaguchi, O. & other authors (2007). Association of the outcome of renal transplantation with antibody response to cytomegalovirus strain-specific glycoprotein H epitopes. Clin Infect Dis 45, 60-67.
25. Klein, M., Schoppel, K., Amvrossiadis, N. & Mach, M. (1999). Strain-specific neutralization of human cytomegalovirus isolates by human sera. J Virol 73, 878-886.
26. Klenovsek, K., Weisel, F., Schneider, A., Appelt, U., Jonjic, S., Messerle, M., Bradel-Tretheway, B., Winkler, T. H. & Mach, M. (2007). Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 110, 3472-3479.
27. Knossow, M. & Skehel, J. J. (2006). Variation and infectivity neutralization in influenza. Immunology 119, 1-7.
28. Lehner, R., Meyer, H. & Mach, M. (1989). Identification and characterization of a human cytomegalovirus gene coding for a membrane protein that is conserved among human herpesviruses. J Virol 63, 3792-3800.
29. Mach, M. (2006). Antibody-mediated neutralization of infectivity. In Cytomegaloviruses: Molecular Biology and Immunology, pp. 265-283. Edited by M. J. Reddehase. Wymondham, UK: Caister Academic Press.
30. Mach, M., Kropff, B., Dal-Monte, P. & Britt, W. J. (2000). Complex formation of human cytomegalovirus glycoprotein M (gpUL100) and glycoprotein N (gpUl73). J Virol 74, 11881-11892.
31. Mach, M., Kropff, B., Kryzaniak, M. & Britt, W. (2005). Complex formation by glycoproteins M and N of human cytomegalovirus: structural and functional aspects. J Virol 79, 2160-2170.
32. Marshall, G. S., Rabalais, G. P., Stout, G. G. & Waldeyer, S. L. (1992). Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J Infect Dis 165, 381-384.
33. Meyer, H., Masuho, Y. & Mach, M. (1990). The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope. J Gen Virol 71, 2443-2450.
34. Meyer, H., Sundqvist, V. A., Pereira, L. & Mach, M. (1992). Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. J Gen Virol 73, 2375-2383.
35. Meyer-Konig, U., Ebert, K., Schrage, B., Pollak, S. & Hufert, F. T. (1998). Simultaneous infection of healthy people with multiple human cytomegalovirus strains. Lancet 352, 1280-1281.
36. Murphy, E., Yu, D., Grimwood, J., Schmutz, J., Dickson, M., Jarvis, M. A., Hahn, G., Nelson, J. A., Myers, R. M. & Shenk, T. E. (2003). Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc Natl Acad Sci U S A 100, 14976-14981.
37. Novak, Z., Ross, S. A., Patro, R. K., Pati, S. K., Kumbla, R. A., Brice, S. & Boppana, S. B. (2008). Cytomegalovirus strain diversity in seropositive women. J Clin Microbiol 46, 882-886.
38. Patrone, M., Secchi, M., Fiorina, L., Ierardi, M.,Milanesi, G. & Gallina, A. (2005). Human cytomegalovirus UL130 protein promotes endothelial cell infection through a producer cell modification of the virion. J Virol 79, 8361-8373.
39. Pignatelli, S., Dal Monte, P., Rossini, G., Chou, S., Gojobori, T., Hanada, K., Guo, J. J., Rawlinson, W., Britt, W. & other authors (2003). Human cytomegalovirus glycoprotein N (gpUL73-gN) genomic variants: identification of a novel subgroup, geographical distribution and evidence of positive selective pressure. J Gen Virol 84, 647-655.
40. Rasmussen, L., Geissler, A., Cowan, C., Chase, A. & Winters, M. (2002). The genes encoding the gCIII complex of human cytomegalovirus exist in highly diverse combinations in clinical isolates. J Virol 76, 10841-10848.
41. Rasmussen, L., Geissler, A. & Winters, M. (2003). Inter- and intragenic variations complicate the molecular epidemiology of human cytomegalovirus. J Infect Dis 187, 809-819.
42. Schoppel, K., Hassfurther, E., Britt, W. J., Ohlin, M., Borrebaeck, C. A. & Mach, M. (1996). Antibodies specific for the antigenic domain 1 (AD-1) of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures. Virology 216, 133-145.
43. Schoppel, K., Kropff, B., Schmidt, C., Vornhagen, R. & Mach, M. (1997). The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies. J Infect Dis 175, 533-544.
44. Schoppel, K., Schmidt, C., Einsele, H., Hebart, H. & Mach, M. (1998). Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. J Infect Dis 178, 1233-1243.
45. Shen, S., Wang, S., Britt, W. J. & Lu, S. (2007). DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates. Vaccine 25, 3319-3327.
46. Shimamura, M., Mach, M. & Britt, W. J. (2006). Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response. J Virol 80, 4591-4600.
47. Simpson, J. A., Chow, J. C., Baker, J., Avdalovic, N., Yuan, S., Au, D., Co, M. S., Vasquez, M., Britt, W. J. & Coelingh, K. L. (1993). Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites. J Virol 67, 489-496.
48. Stanton, R., Westmoreland, D., Fox, J. D., Davison, A. J. & Wilkinson, G. W. (2005). Stability of human cytomegalovirus genotypes in persistently infected renal transplant recipients. J Med Virol 75, 42-46.
49. Talbot, P. & Almeida, J. D. (1977). Human cytomegalovirus: purification of enveloped virions and dense bodies. J Gen Virol 36, 345-349.
50. Urban, M., Britt, W. & Mach, M. (1992). The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific. J Virol 66, 1303-1311.
51. Urban, M., Klein, M., Britt, W. J., Hassfurther, E. & Mach, M. (1996). Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol 77, 1537-1547.
52. Varnum, S. M., Streblow, D. N., Monroe, M. E., Smith, P., Auberry, K. J., Pasa-Tolic, L., Wang, D., Camp, D. G., Rodland, K. & other authors (2004). Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol 78, 10960-10966.
53. Waner, J. L. & Weller, T. H. (1978). Analysis of antigenic diversity among human cytomegaloviruses by kinetic neutralization tests with high-titered rabbit antisera. Infect Immun 21, 151-157.
54. Wang, D. & Shenk, T. (2005). Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 79, 10330-10338.
55. Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F., Salazar, M. G., Kilby, J. M. & other authors (2003). Antibody neutralization and escape by HIV-1. Nature 422, 307-312.
56. Zinkernagel, R. M. & Hengartner, H. (2006). Protective 'immunity' by pre-existent neutralizing antibody titers and preactivated T cells but not by so-called 'immunological memory'. Immunol Rev 211, 310-319.